CRF Health’s Platform Selected in Phase III Diabetes Trial
CRF Health, a provider of eCOA solutions for the life sciences industry, announced its TrialMax® eCOA platform has been selected by a sponsor to capture more than 4.6 million data points via an integrated medical device in a Phase III diabetes program. The program encompasses 3,000 patients across 450 sites in 28 countries using diabetes care devices and patient diaries. Read the full release.
CRF Health, a provider of eCOA solutions for the life sciences industry, announced its TrialMax® eCOA platform has been selected by a sponsor to capture more than 4.6 million data points via an integrated medical device in a Phase III diabetes program. The program encompasses 3,000 patients across 450 sites in 28 countries using diabetes care devices and patient diaries.
Read the full
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
Everything to Know About FDA’s Push Towards Radical Transparency in 2025September 17th 2025
IQVIA and Veeva Join Forces to Improve Efficiency and Patient OutcomesSeptember 17th 2025
Managing Background Therapies in the NIMBLE Phase III TrialSeptember 17th 2025
Generative AI Transforms Clinical Study Report DevelopmentSeptember 16th 2025
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
